Heart failure & cardiomyopathies
IL-6 and hsCRP Predict Cardiovascular Mortality in Patients with Heart Failure with Preserved Ejection Fraction
Authors' conclusion
These data suggest a predictive value of elevated IL-6 for CV-mortality in HFpEF but not in HFrEF patients.
Study context
- Population
- Patients with heart failure (HF) referred for coronary angiography (LURIC study)
- Participants
- 1,086 patients
- Exposure
- Prognostic value of IL-6 and hsCRP in HFpEF vs HFrEF
- HFpEFn = 506
- HFrEFn = 580
- Outcome
- CV mortality
Main finding
As reported in the abstract
CV mortality with increasing IL-6
Hazard ratio (95% CI)P value
HFrEFIL-6, HFrEF
1.3(1.0–1.7)
P = 0.06- HFpEF · IL-6, HFpEF
- 1.5 (95% CI 1.1–2.2); P = 0.018
Observational data: associations, not effects.
Further findings
CV mortality with hsCRP (fully adjusted)
| HR (95% CI) | P value | ||
|---|---|---|---|
| HFpEFhsCRP, HFpEF | 1.4 (1.0–2.0) | P = 0.065 | |
| HFrEFhsCRP, HFrEF | 1.0 (0.7–1.3) | P = 0.800 | |
| 0.512Hazard ratio (log scale) |
CV mortality by IL-6 and N terminal pro brain natriuretic peptide (NT-proBNP) above/below median (interaction analysis)
- Stepwise increase in CV mortality in HFpEF
- P = 0.036
- No stepwise increase in HFrEF
- P = 0.220
NT-proBNP, IL6-Receptor p.Asp358Ala (rs2228145) homozygous vs wildtype carriers
- HFpEF: homozygous 779 pg/mL ± 787 vs wildtype 1180 pg/ mL ± 1532
- P = 0.008
- HFrEF: homozygous 2289 pg/ mL ± 3439 vs wildtype 2326 pg/ mL ± 3386
- P = 0.94
Original publication
IL-6 and hsCRP Predict Cardiovascular Mortality in Patients with Heart Failure with Preserved Ejection Fraction. ESC Heart Fail. Published 14 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →